March 04, 2015 9:51 PM ET


Company Overview of MacroGenics, Inc.

Company Overview

MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. Its products include Margetuximab, a monoclonal antibody that targets human epidermal growth factor receptor 2-expressing tumors, including breast, gastroesophageal, bladder, and other cancers; MGA271, an Fc-optimized monoclonal antibody for various solid tumor types; MGD006, a humanized dual affinity re-targeting (DART) molecule for the treatment of hematologic cancers; and MGD007, a DART protein to treat colorectal cancer. The company’s products also comprise Teplizumab, a humanized anti-CD3 monoclon...

9640 Medical Center Drive

Rockville, MD 20850

United States

Founded in 2000





Key Executives for MacroGenics, Inc.

Chief Executive Officer, President and Director
Age: 62
Total Annual Compensation: $456.1K
Chief Financial Officer, Senior Vice President and Secretary
Age: 46
Total Annual Compensation: $306.7K
Senior Vice President of Clinical Development
Age: 52
Total Annual Compensation: $148.6K
Compensation as of Fiscal Year 2013.

MacroGenics, Inc. Key Developments

MacroGenics, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Update on Corporate Progress

MacroGenics, Inc. reported consolidated earnings results for the year ended December 31, 2014. For the period, the company reported total revenue of $47,797,000, loss from operations of $38,315,000, net comprehensive loss of $38,313,000 or $1.40 per basic and diluted share compared to total revenue of $58,035,000, income from operations of $366,000, net comprehensive income of $261,000 or $0.04 per basic and diluted share a year ago. The company provided update corporate progress. Phase 3 Metastatic Breast Cancer Study: The company expects to commence SOPHIA, a Phase 3 pivotal study in approximately 530 subjects, in the third quarter of 2015. This study is planned to evaluate margetuximab plus chemotherapy against trastuzumab plus chemotherapy in third-line metastatic breast cancer patients with HER2 expression at the 3+ level by immunohistochemistry (IHC) or 2+ level by IHC with gene amplification, subject to completion of further regulatory review. MacroGenics projects that it will take approximately three years to complete this study, which will include an interim futility analysis. Presentation of Phase 1 Data: In mid-2015, MacroGenics plans to present margetuximab Phase 1 clinical data for patients with breast cancer in expansion cohorts testing once-every-three-week dosing regimens. MGA271 is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules involved in immune regulation. Presentation of Phase 1 MGA271 Data: In the second half of 2015, MacroGenics plans to present Phase 1 clinical data for MGA271. Combination Studies: MacroGenics plans to initiate studies of MGA271 in combination with other immuno-oncology agents in 2015, including a combination study with ipilimumab in B7-H3 positive melanoma, lung, and head and neck cancers. MGD006 is a humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, is expressed on leukemia and leukemic stem cells. The primary mechanism of action of MGD006 is its ability to redirect T cells, via their CD3 component, to kill CD123-expressing cells. MacroGenics continues to enroll patients in the dose escalation portion of a Phase 1 study of MGD006 for the treatment of acute myeloid leukemia. MGD007 is a humanized DART molecule that recognizes both the glycoprotein A33 antigen, or gpA33, and CD3. The primary mechanism of action of MGD007 is its ability to redirect T cells, via their CD3 component, to kill gpA33-expressing cells. MacroGenics continues to enroll patients in the dose escalation portion of a Phase 1 study of MGD007 for the treatment of colorectal cancer. MacroGenics' pipeline of earlier DART candidates continues to progress. In addition to MGD011, which was recently licensed to Janssen Biotech, Inc., the company expects that both MGD010 and MGD009 will start in Phase 1 clinical studies in 2015. Details of these programs include: MGD010 Nearing Phase 1 Clinical Initiation: MGD010 is a DART molecule for the treatment of autoimmune disorders that simultaneously targets CD32B and CD79B, which are two B-cell surface proteins. MGD010 is designed to inhibit B-cell activation by exploiting the inhibitory function of CD32B, a checkpoint molecule expressed by B cells. MacroGenics expects to initiate a Phase 1a study in normal healthy volunteers in the first half of 2015. This product candidate is subject to a global collaboration with Takeda. Introducing MGD009: In late 2015, MacroGenics anticipates initiating a Phase 1 clinical study of MGD009, a humanized DART molecule that recognizes both CD3 and an undisclosed antigen expressed on many solid tumor types. MacroGenics retains worldwide development and commercialization rights to this molecule.

MacroGenics, Inc. to Report Q4, 2014 Results on Mar 03, 2015

MacroGenics, Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Mar 03, 2015

MacroGenics, Inc., Q4 2014 Earnings Call, Mar 03, 2015

MacroGenics, Inc., Q4 2014 Earnings Call, Mar 03, 2015

Similar Private Companies By Industry

Company Name Region
Bracken, Foster & Associates, LLC United States
Nitto Americas, Inc. United States
Velcera, Inc. United States
ProhibiTx, Inc. United States
Asklepios BioPharmaceutical, Inc. United States

Recent Private Companies Transactions

Private Placement
December 19, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MacroGenics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at